With a more sophisticated understanding of TP53 alteration biology and its determinants of the patient outcomes, future randomized trials employing novel agents could soon establish a true standard of care for TP53m-AML, a disease that, to date, has served as the chief example of poor-risk AML. The gene discussed is TP53; the disease is acute myeloid leukemia.